In silico evaluation of natural bioactive compounds as Mycobacterium leprae enoyl acyl carrier protein reductase inhibitors


  • Haitham Al-Madhagi Biochemistry teaching assistant, Biochemical Technology Program, Thamar University, Dhamar, Yemen


Background and Objectives:

The present study was designed to assess the antileprotic effectiveness of some bioactive natural compounds towards enoyl acyl carrier protein reductase inhibition. Leprosy still constitutes a global pandemic in spite of long years of discovery. The current therapy option is multi-drug treatment using a combination of Dapsone, Rifampicin and Clofazimine. However, mycobacterium leprae counteracted by mutating the drug targets which necessitates the search for novel targets. One such target is enoyl acyl carrier protein reductase that mediates the fatty acid biosynthesis.

Materials and Methods:

Multiple (14) ligands of natural origin were drawn from PubChem database and their ADMET parameters were preicted using ADMETLab 2.0 webserver. After, the ligands were docked against the enzyme (PDB ID: 2NTV) at its active site using iGEMDOCK software.


ADMET parameters of the tested ligands proven to be accepted by Lipinski's rule of five except for two ligands. Furthermore, molecular docking results revealed that all of the tested compounds showed better binding energy than the reference drug Dapsone. The best of which was silymarin.


The tested natural ligands have the capability to control M.leprae.


Download data is not yet available.


Rodrigues LC, Lockwood DN. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 2011;11:464–70.

Polycarpou A, Walker SL, Lockwood DN. New findings in the pathogenesis of leprosy and implications for the management of leprosy. Curr Opin Infect Dis 2013;26:413–9.

de Macedo CS, Lara FA, Pinheiro RO, Schmitz V, de Berrêdo-Pinho M, Pereira GM, et al. New insights into the pathogenesis of leprosy: contribution of subversion of host cell metabolism to bacterial persistence, disease progression, and transmission. F1000Research 2020;9.

Aarão TL de S, de Sousa JR, Falcão ASC, Falcão LFM, Quaresma JAS. Nerve growth factor and pathogenesis of leprosy: review and update. Front Immunol 2018;9:939.

Mungroo MR, Khan NA, Siddiqui R. Mycobacterium leprae: Pathogenesis, diagnosis, and treatment options. Microb Pathog 2020;149:104475.

Maymone MB, Venkatesh S, Laughter M, Abdat R, Hugh J, Dacso MM, et al. Leprosy: Treatment and management of complications. J Am Acad Dermatol 2020;83:17–30.

Cambau E, Carthagena L, Chauffour A, Ji B, Jarlier V. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin Infect Dis 2006;42:238–41.

Zitko J, Doležal M. Enoyl acyl carrier protein reductase inhibitors: An updated patent review (2011–2015). Expert Opin Ther Pat 2016;26:1079–94.

Lockwood DN, Saunderson PR. Nerve damage in leprosy: a continuing challenge to scientists, clinicians and service providers. Int Health 2012;4:77–85.

Lechartier B, Cole ST. Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015;59:4457–63.

Cambau E, Saunderson P, Matsuoka M, Cole ST, Kai M, Suffys P, et al. Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clin Microbiol Infect 2018;24:1305–10.

Acebrón-García-de-Eulate M, Blundell TL, Vedithi SC. Strategies for drug target identification in Mycobacterium leprae. Drug Discov Today 2021;26:1569–73.

Spyrakis F, Bellio P, Quotadamo A, Linciano P, Benedetti P, D’Arrigo G, et al. First virtual screening and experimental validation of inhibitors targeting GES-5 carbapenemase. J Comput Aided Mol Des 2019;33:295–305.

Ranganathan S, Nakai K, Schonbach C. Encyclopedia of Bioinformatics and Computational Biology: ABC of Bioinformatics. Elsevier; 2018.

Singh TR, Shukla A, Taoufik B, Moussa A, Vannier B. Provided for non-commercial research and educational use. Not for reproduction, distribution or commercial use. 2019.

Ali Raza Naqvi S, Nadeem S, Komal S, Ali Asad Naqvi S, Samee Mubarik M, Yaqub Qureshi S, et al. Antioxidants: Natural Antibiotics. In: Shalaby E, editor. Antioxidants, IntechOpen; 2019.

Parham S, Kharazi AZ, Bakhsheshi-Rad HR, Nur H, Ismail AF, Sharif S, et al. Antioxidant, Antimicrobial and Antiviral Properties of Herbal Materials. Antioxid Basel Switz 2020;9:E1309.

Wang F, Langley R, Gulten G, Dover LG, Besra GS, Jacobs WR, et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med 2007;204:73–8.

O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminformatics 2011;3:1–14.

Hsu K-C, Chen Y-F, Lin S-R, Yang J-M. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics 2011;12:1–11.

Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res 2021;49:W5–14.

James WD, Elston DM, Berger TG, Andrews GC. Andrews’ Diseases of the skin: clinical dermatology. London: Saunders Elsevier; 2011.

Paraman TK, Murugesen T, Perumal VN. Drug targets in leprosy 2016.

Pires DE, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015;58:4066–72.

Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, et al. Massive gene decay in the leprosy bacillus. Nature 2001;409:1007–11.



How to Cite

Al-Madhagi, H. (2022). In silico evaluation of natural bioactive compounds as Mycobacterium leprae enoyl acyl carrier protein reductase inhibitors. Journal of Chemistry and Nutritional Biochemistry, 3(1), 1–10.